RE:Q4 Numbers And Forward looking Info, Your welcomeYes, N's sales are growing nicely but your numbers are flawed. First of all, use market cap and not share price when comparing companies. Secondly, N's quarters end in Sept and Dec, NOT Aug and Nov. This quarter's revenues are almost as high in two months (Oct and Nov) than last quarter's revenue was in 3 months (July, Aug, Sept), so yes, this quarter will be their best quarterly revenues ever. Another problem with comparing N to that group of stocks is that N does not yet sell MJ and most of those other ones do.
BB
Discomuff wrote: Q4 Results look something like this
1)June 2017 $1,349,545.00 Can
2)July 2017 $1,196,971.00 Can
3)August 2017 $1,426,755.00 Can
Totaling $3,969,675.00 Can
Acording to the Revenue tracker this still places us in 9th place as followed,
Company / Quarterly Revenue / Share Price
1) Canopy Growth / 17.57M / $23.12
2) MedReleaf / 9.82M / $16.34
3) Aurora / 8.25M / $7.21
4) Canntrust / 6.14M / $8.35
5) Aphria/ 6.12M / $15.28
6) Isodiol International / 5.06M / $1.33
7) Cannimed Therapeutics / 4.77M / $19.95
8) MPX Bioceutical / 4.41M / $.44
9) NamasteTechnologies / 3.96M / $2.66
This is an increase from the Q3 results of about $3,130,00.00
Forward Looking into Q1 2018
1) September $1,198,765 Can
2) October $1,313,653 Can
3) November $2,221,340 Can
Totaling $4,733,758
As you can see the company is on track moving forward with future growth and revenue.
Q2 2018 and Q3 2018 will be very exciting times and we are going to see a whole new added revenue stream from medical Cannabis sales which will be doubling or tripling Quartery results